Ascendis Pharma – a platinum sponsor of the Joint Congress of ESPE and ESE 2025.
Ascendis Pharma is a global biopharmaceutical company committed to making a meaningful difference in patients’ lives. Guided by our core values of Patients, Science, and Passion, we are applying our innovative TransCon® technology platform to fulfill our mission of developing new therapies that demonstrate best-in-class potential to address unmet medical needs.
At our headquarters in Hellerup, Denmark, research facilities in Heidelberg, Germany, and additional offices across Europe and the United States, we are advancing programs in our Endocrinology Rare Disease and Oncology portfolios.
We also collaborate with partners on the development of TransConbased products in other therapeutic areas and markets.

Find us at booth 16 in the exhibition hall E.
All further details below will be available on this webpage too – however provided by the Congress Secretariat Interplan.
Congress activities
Monday, 12 May 2025, 13:00 – 14:40, Room D5
Beyond Conventional Care: Redefining Treatment Success in Chronic Hypoparathyroidism – An Ascendis Pharma sponsored satellite symposium.
Agenda Overview:
Welcome & introduction
Why it’s time to rethink treatment goals in chronic hypoparathyroidism
Importance of quality-of-life considerations in treatment of chronic hypoparathyroidism
Knowns and unknowns about skeletal dynamics in chronic hypoparathyroidism
Effect of PTH replacement on renal function in chronic hypoparathyroidism – Addressing a long-term challenge
Closing remarks
Sunday, 11 May 2025, 15:55 – 17:25, Room C2
Assessing HRQoL in Achondroplasia Across the Life Course – An Ascendis Pharma sponsored satellite symposium.
Agenda Overview:
Opening remarks
Understanding HRQol in achondroplasia
Current tools and methodologies
Challenges and gaps in HRQol assessment
Innovative approaches and future directions
Closing remarks
Sunday, 11 May 2025, 09:55 – 10:25, Foyer F5 – Pop Up Theatre
Restoring Physiological Levels of PTH in Chronic Hypoparathyroidism – An Ascendis Pharma sponsored Product Theatre.
Agenda overview:
Opening Remarks
Chronic Hypoparathyroidism: One Disease, Multiple Consequences
Replacing the Missing PTH in Chronic Hypoparathyroidism